12 Results for "

Rec-1

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "Rec-1" in MCE Product Catalog:

10
10 Cited Publications
Cat. No.: HY-137471
CAS No.: 2682114-39-0
Purity:  99.80%
Synonyms: RIN1
Target:  

Notch

연구분야:  

Cancer

RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation [1].
loading...
    loading...
Cat. No.: HY-136250
CAS No.: 2349356-09-6
Purity:  99.76%
Target:  

PROTACs CDK

연구분야:  

Cancer

BSJ-03-204 is a PROTAC linking a Cereblon ligand to a CDK ligand, serving as a potent and selective dual degrader of CDK4/6. BSJ-03-204 exhibits IC50 values of 26.9 nM and 10.4 nM against CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 can be utilized for cancer-related research [1].
loading...
    loading...
Cat. No.: HY-148683
CAS No.: 2377113-41-0
Purity:  98.77%
Target:  

Arp2/3 Complex

연구분야:  

Cancer

EG-011 is the first-in-class and potent Wiskott-Aldrich syndrome protein (WASP) activator. EG-011 activates the auto-inhibited form of WASP with strong actin polymerization. EG-011 has selective anti-tumor activity in lymphomas [1] .
loading...
    loading...
Cat. No.: HY-137438
CAS No.: 1858206-58-2
Purity:  99.75%
Synonyms: TG-1701
Target:  

Btk

연구분야:  

Cancer

Edralbrutinib (TG-1701) is a highly selective, orally available irreversible BTK inhibitor, with an EC50 of 6.70 nM and a Kd of 3 nM against human BTK. Edralbrutinib inhibits downstream signaling of the B cell receptor, induces dephosphorylation of Ikaros Ser442/445, promotes nuclear exclusion of Ikaros, attenuates Ikaros gene signatures, and exerts anti-tumor activity. Edralbrutinib can be used in research related to B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma [1] .
loading...
    loading...
Cat. No.: HY-174850
CAS No.: 2941611-57-8
Target:  

Btk

연구분야:  

Cancer

CFON-026 is a selective, orally active and non-covalent BTK inhibitor with an IC50 of 0.27  nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L). CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia [1] .
loading...
    loading...
Cat. No.: HY-136250A
Purity:  99.87%
Target:  

PROTACs CDK

연구분야:  

Cancer

BSJ-03-204 triTFA is a PROTAC connected by ligands for Cereblon and CDK. BSJ-03-204 triTFA is a potent and selective Palbociclib-based CDK4/6 dual degrader (PROTAC), with IC50s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 triTFA does not induce IKZF1/3 degradation and has anti-cancer activity [1].
loading...
    loading...
Cat. No.: HY-172430S
CAS No.: 1918159-31-5
Epaldeudomide (Compound A406) is the inhibitor for TNF-α (>50% inhibition rate at 100 nM). Epaldeudomide inhibits the proliferation of cancer cells MM.1S (IC50 < 300 nM), WSU-DLCL-2 (IC50 < 100 nM) and Rec-1 (IC50 < 100 nM). Epaldeudomide exhibits antineoplastic activity [1].
loading...
    loading...
Cat. No.: HY-174129
CAS No.: 2649008-95-5
Target:  

Btk Apoptosis

연구분야:  

Cancer

TM471-1 is an orally active and covalent Bruton's tyrosine kinase (BTK) inhibitor with IC50 values of 1.3 nM (BTK WT), >40,000 nM (BTK C481S), 7.9 nM (TEC) and 12.4 nM (TXK). TM471-1 inhibits cell growth in vivo and in vitro, arrests cell cycle at G0/G1 phase and induces cell apoptosis [1].
loading...
    loading...
Cat. No.: HY-RS11596
연구분야:  

Others

RAD1 Human Pre-designed siRNA Set A contains three designed siRNAs for RAD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS20597
연구분야:  

Others

Slc7a1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Slc7a1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-181623
CAS No.: 3114684-06-6
Target:  

PROTACs Btk

연구분야:  

Cancer

PROTAC BTK degrader-14 (compound 112) is a PROTAC protein degrader targeting BTK. PROTAC BTK degrader-14 can be used for the research of cancer [1].
loading...
    loading...
Cat. No.: HY-181547
CAS No.: 2963606-11-1
Target:  

Btk

연구분야:  

Cancer

HBC-12551 is an orally active BTK inhibitor (IC50 in HEK293 cells: 1.31 nM for BTK; 2.18 nM for BTK C481S). HBC-12551 has antitumor activity against diffuse large B-cell lymphoma [1].
loading...
    loading...
  • 1